Ramkumar Rajendran
Overview
Explore the profile of Ramkumar Rajendran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prakash A, Rajendran R
IEEE Trans Vis Comput Graph
. 2025 Mar;
PP.
PMID: 40063483
The integration of immersive Virtual Reality (I-VR) technology in education has emerged as a promising approach for enhancing learning experiences. There is a handful of research done to study the...
2.
Tan S, Rajendran R, Bhattamisra S, Krishnappa P, Davamani F, Chitra E, et al.
Nat Prod Res
. 2024 Feb;
:1-8.
PMID: 38340357
Progressive decline in β cell function and reduction in the β cell mass is important in type 2 diabetes. Here, we tested the hypothesis that madecassoside's previously demonstrated protective effects...
3.
Tan S, Rajendran R, Bhattamisra S, Krishnappa P, Davamani F, Chitra E, et al.
J Pharm Pharmacol
. 2023 Jul;
75(8):1034-1045.
PMID: 37402616
Objectives: Madecassoside (MAD) is a triterpenoid constituent of Centella asiatica (L.) Urb., an ethnomedical tropical plant, extracts of which were shown to reduce blood glucose in experimental diabetes. This study...
4.
Garg A, Rajendran R
Educ Inf Technol (Dordr)
. 2023 Jun;
:1-17.
PMID: 37361835
Procrastination is one of the issues affecting more than half of the student population and is known to impact them negatively. It is also one of the major reasons for...
5.
Rahman R, Fonseka A, Sua S, Ahmad M, Rajendran R, Ambu S, et al.
J Cell Mol Med
. 2021 Jul;
25(15):7181-7189.
PMID: 34236134
Breast cancer has a diverse aetiology characterized by the heterogeneous expression of hormone receptors and signalling molecules, resulting in varied sensitivity to chemotherapy. The adverse side effects of chemotherapy coupled...
6.
Garva R, Thepmalee C, Yasamut U, Sudsaward S, Guazzelli A, Rajendran R, et al.
Front Oncol
. 2019 Oct;
9:949.
PMID: 31608237
The class III NAD dependent deacetylases-sirtuins (SIRTs) link transcriptional regulation to DNA damage response and reactive oxygen species generation thereby modulating a wide range of cellular signaling pathways. Here, the...
7.
Lee E, Elhassan S, Ling Lim G, Kok W, Tan S, Leong E, et al.
Biomed Pharmacother
. 2018 Dec;
111:198-208.
PMID: 30583227
For many years, circular ribonucleic acids (circRNAs) have been counted as aberrant splicing by-products. Advanced bioinformatics analysis and deep sequencing techniques have allowed researchers to discover more interesting facts about...
8.
Qattan M, Bakker E, Rajendran R, Chen D, Saha V, Liu J, et al.
PLoS One
. 2017 Jun;
12(6):e0178606.
PMID: 28582465
Glucocorticoids (GCs) and topoisomerase II inhibitors are used to treat acute lymphoblastic leukaemia (ALL) as they induce death in lymphoid cells through the glucocorticoid receptor (GR) and p53 respectively. Mechanisms...
9.
Leung T, Rajendran R, Singh S, Garva R, Krstic-Demonacos M, Demonacos C
Breast Cancer Res
. 2013 Nov;
15(6):R107.
PMID: 24207099
Introduction: The cytochrome P450 (CYP) enzymes are a class of heme-containing enzymes involved in phase I metabolism of a large number of xenobiotics. The CYP family member CYP2E1 metabolises many...
10.
Tian K, Rajendran R, Doddananjaiah M, Krstic-Demonacos M, Schwartz J
PLoS One
. 2013 Sep;
8(9):e72303.
PMID: 24023735
Chemotherapy is commonly used in cancer treatments, however only 25% of cancers are responsive and a significant proportion develops resistance. The p53 tumour suppressor is crucial for cancer development and...